{"filing":{"accession_number":"0001213900-26-077607","cik":"0002023311","ticker":"AAPG","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","form":"6-K","filing_date":"2026-07-13","report_date":null,"primary_document":"ea0297882-6k_ascentage.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023311/000121390026077607/ea0297882-6k_ascentage.htm"},"events":[{"id":17643,"run_id":15810,"accession_number":"0001213900-26-077607","anchor_item_number":"EX-99.1","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"This announcement updates the grant of RSUs (Restricted Stock Units) under the 2021 and 2022 RSU Schemes and options under the Post IPO Share Option Scheme. The disclosure concerns equity compensation awards to executives and employees, which falls squarely within executive compensation. The material correction of the AGM date (May 19, 2025 vs. May 20, 2026) clarifies the authorization basis for these equity grants, making this a material disclosure affecting investor understanding of executive incentive arrangements.","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-07-13","form":"6-K","submitted_at":null,"items":[{"id":16196,"accession_number":"0001213900-26-077607","item_number":"EX-99.1","item_title":"ea029788201ex99-1.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This announcement updates the grant of RSUs (Restricted Stock Units) under the 2021 and 2022 RSU Schemes and options under the Post IPO Share Option Scheme. The disclosure concerns equity compensation awards to executives and employees, which falls squarely within executive compensation. The material correction of the AGM date (May 19, 2025 vs. May 20, 2026) clarifies the authorization basis for these equity grants, making this a material disclosure affecting investor understanding of executive incentive arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:48:56.182414+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16196,"accession_number":"0001213900-26-077607","item_number":"EX-99.1","item_title":"ea029788201ex99-1.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This announcement updates the grant of RSUs (Restricted Stock Units) under the 2021 and 2022 RSU Schemes and options under the Post IPO Share Option Scheme. The disclosure concerns equity compensation awards to executives and employees, which falls squarely within executive compensation. The material correction of the AGM date (May 19, 2025 vs. May 20, 2026) clarifies the authorization basis for these equity grants, making this a material disclosure affecting investor understanding of executive incentive arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:48:56.182414+00:00","company_name":"ASCENTAGE PHARMA GROUP INTERNATIONAL","ticker":"AAPG","filing_date":"2026-07-13"}]}